We are a market leading, pioneering immunology business with specialist experience in the research and development of allergy treatments.
|Admission date:||10 Oct 2004|
|17 Oct 2022||General Meeting|
|26 Jul 2022||Investor Presentation|
No Results & Reports data for this company